AMAG Pharmaceuticals, Inc. (AMAG)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

1100 WINTER STREET WALTHAM, MA 02451

AMAG Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). Co.'s principal product is Feraheme (ferumoxytol) Injection for Intravenous (IV) use, which is used as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease. Co. markets and sells Feraheme in the U.S. through its own commercial organization, including a sales force. Co. also markets and sells GastroMARK, under the trade name Lumirem outside of the U.S. GastroMARK is Co.'s oral contrast agent used for delineating the bowel in magnetic resonance imaging.

Data based on most recent fiscal year report
Market Cap719.78 Million Shares Outstanding35.37 Million Avg Volume1.734 Million
1-Yr BETA vs S&P TR Current Ratio1.74 Quick Ratio1.6
View SEC Filings from AMAG instead.
Q2 2019 All Institutions Hedge Funds 1
To trade AMAG now:
Filers who had this stock in their top 10: 0 2 (0.21%)
13F Filers holding this stock: 166 30 (3.1%)
Aggregate 13F shares on 06/30/2019: 40.653 Million 15.509 Million
Aggregate 13F shares on 03/31/2019: 40.319 Million 14.836 Million
Percent change: 0.83% 4.54%
Funds creating new positions: 27 9
Funds Adding to an existing position: 59 10
Funds closing out their position: 21 6
Funds reducing their position: 58 11
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AMAG (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL MASTER FUND LTD.

BOYD STEVEN

  • Director
  • 10% Owner
0 2019-10-11 2

PEREZ ROBERT J

  • Director
0 2019-10-10 1

FONTEYNE PAUL R.

  • Director
4,407 2019-10-08 2

JOHNSON DAVID EDWARD

  • Director
  • 10% Owner
3,503,835 2019-10-08 1

ALLEN LEE F MD PHD CHIEF MEDICAL OFFICER

9,635 2019-09-30 0

ARKOWITZ DAVID

  • Director
28,831 2019-09-30 0

LOBERG MICHAEL D

  • Director
39,803 2019-09-18 0

CASCIANO ANTHONY CHIEF COMMERCIAL OFFICER

  • Officer
59,477 2019-09-04 3

SHEA KENNETH

  • 10% Owner
  • SEE REMARKS
5,000 2019-09-04 1

CROUSE GEOFFREY

  • Director
29,259 2019-08-22 0

CALIGAN PARTNERS LP

MERKSAMER SAMUEL J.

JOHNSON DAVID EDWARD

  • 10% Owner
3,499,428 2019-08-12 1

CAMBER CAPITAL MANAGEMENT LP

4,390,000 2019-08-07 2

HEIDEN WILLIAM K

  • Director
12,500 2019-06-27 4

THOMAS FRANK E

  • Director
0 2019-06-26 0

SCOON DAVEY

  • Director
0 2019-06-21 1

SANTINI GINO

  • Director
7,284 2019-06-20 1

SULAT JAMES R

  • Director
54,090 2019-06-19 1

O'BRIEN KATHRINE

  • Director
10,566 2019-06-14 3

KELLEY BRIAN P

  • Director
62,419 2019-06-13 0

NARACHI MICHAEL

  • Director
9,750 2019-06-11 0

FALLON JOHN A.

  • Director
13,469 2019-05-30 1

KROP JULIE CHIEF MEDICAL OFFICER

  • Officer
81,399 2019-05-28 4

MYLES EDWARD H

  • Director
0 2019-05-21 4

DEPTULA BARBARA

  • Director
26,354 2019-05-16 1

PHILLIPS ANNE M.

  • Director
8,680 2019-05-16 3

BOLGIANO ELIZABETH SCOTT CHIEF HUMAN RESOURCES OFFICER

  • Officer
74,847 2019-05-09 4

BUTCHER JAMES ALAN EVP, CHIEF BUSINESS OFFICER

  • Officer
50,628 2019-04-30 2

VITTIGLIO JOSEPH EVP, GENERAL COUNSEL

  • Officer
78,955 2019-03-07 4

GRUND NICHOLAS CHIEF COMMERCIAL OFFICER

  • Officer
84,805 2019-03-02 4

RUSSELL LESLEY

  • Director
0 2019-02-28 0

PEREIRA BRIAN JG

  • Director
0 2019-02-01 0

FARMER JOSEPH L SR VP, GEN COUNSEL & SECRETARY

  • Officer
0 2019-01-22 0

HOLMES SCOTT A CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2018-12-12 0

MADISON GREG PRESIDENT AND CEO

  • Officer
  • Director
566,586 2018-03-20 0

HEALEY TIMOTHY G SVP, COMMERCIAL

  • Officer
85,658 2018-03-05 0

ADAGE CAPITAL PARTNERS GP, L.L.C.

ADAGE CAPITAL PARTNERS, L.P.

ADAGE CAPITAL ADVISORS, L.L.C.

ATCHINSON ROBERT

GROSS PHILLIP

  • 10% Owner
No longer subject to file 2017-12-31 0

ENGLISH EDWARD C VP OF FINANCE & ADMINISTRATION

  • Officer
396 2017-09-06 0

DE SILVA RAJIV PRESIDENT & CEO

  • Officer
  • Director
355,010 2016-03-18 0

WILSON KENNETH H SVP, SALES AND MARKETING

  • Officer
23,387 2015-12-02 0

TOWNSEND SCOTT B SVP, GENERAL COUNSEL

  • Officer
56,851 2015-03-03 0

JORDAN EDWARD P. SVP, SALES AND MARKETING

  • Officer
39,213 2015-03-03 0

CAFFE STEVEN SVP, CH. DEV. AND REG. OFFICER

  • Officer
59,400 2014-08-19 0

WHITE CHRISTOPHER G CHIEF BUSINESS OFFICER

  • Officer
28,400 2014-02-27 0

SKALETSKY MARK B

  • Director
No longer subject to file 2013-11-13 0

BONVENTRE JOSEPH VINCENT

  • Director
0 2012-05-23 0

ZWANZIGER RON CHAIRMAN, CEO & PRESIDENT

  • Officer
  • Director
3,523,202 2011-11-21 0

ZIEZIULA GARY J EVP, CHIEF COMMERCIAL OFFICER

  • Officer
2,500 2011-07-29 0

ZAYAS RICARDO SVP, OPERATIONS

  • Officer
0 2011-01-07 0

LEWIS JEROME M SVP OF SCIENTIFIC OPERATIONS

  • Officer
0 2008-08-05 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

JOHNSON DAVID EDWARD - Director - > 10% Owner

2019-10-08 A 4,407 a 4,407 3,503,835.00 direct

FONTEYNE PAUL R. - Director

2019-10-08 A 4,407 a 4,407 4,407.00 direct

JOHNSON DAVID EDWARD - Director - > 10% Owner

2019-10-08 A 9,452 a 9,452 3,503,835.00 direct

FONTEYNE PAUL R. - Director

2019-10-08 A 9,452 a 9,452 4,407.00 direct

JOHNSON DAVID EDWARD - Director - > 10% Owner

2019-10-08 A 6,000 a 6,000 3,503,835.00 direct

FONTEYNE PAUL R. - Director

2019-10-08 A 6,000 a 6,000 4,407.00 direct

CASCIANO ANTHONY - Officer CHIEF COMMERCIAL OFFICER

2019-09-06 F 982 $11.83 d 59,477 59,477.00 direct

CASCIANO ANTHONY - Officer CHIEF COMMERCIAL OFFICER

2019-09-04 F 393 $11.24 d 60,459 59,477.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments